The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tinengotinib (TT-00420) in advanced/metastatic FGFR2-altered cholangiocarcinoma following prior chemotherapy and FGFR inhibitor treatment: Results from a phase II study (FIRST-08).
 
Jun Zhou
No Relationships to Disclose
 
Jiajia Yuan
No Relationships to Disclose
 
Lan Zhang
No Relationships to Disclose
 
Qing Zhu
No Relationships to Disclose
 
Ming Yang
No Relationships to Disclose
 
Hao Chen
No Relationships to Disclose
 
Weimin Ding
No Relationships to Disclose
 
Xielin Feng
No Relationships to Disclose
 
Kui Wang
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Yanru Qin
No Relationships to Disclose
 
Weiwei Kong
No Relationships to Disclose
 
Qi Xu
No Relationships to Disclose
 
Zengqing Guo
No Relationships to Disclose
 
Hong Zhao
No Relationships to Disclose
 
Yujia Zhu
Employment - TransThera Sciences (Nanjing), Inc.
 
Caixia Sun
Employment - TransThera Sciences (Nanjing), Inc.
 
Jean Fan
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
Stock and Other Ownership Interests - AstraZeneca
 
Lin Shen
No Relationships to Disclose